Cue Biopharma Announces Pricing of $10 Million Public Offering

Core Viewpoint - Cue Biopharma, Inc. has announced a public offering of 35,714,286 shares of common stock at a price of $0.28 per share, aiming to raise approximately $10 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering includes pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares [1]. - Each common stock warrant will have an exercise price of $0.30 per share, will be exercisable immediately, and will expire five years from the date of issuance [1]. - The offering is expected to close on or about December 22, 2025, subject to customary closing conditions [1]. Group 2: Underwriters - H.C. Wainwright & Co. is acting as the sole book-running manager for the offering, while Newbridge Securities Corporation is serving as co-manager [2]. Group 3: Regulatory Information - The securities are being offered under an effective shelf registration statement on Form S-3 filed with the SEC on May 9, 2023, and declared effective on May 26, 2023 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and can be accessed for free on the SEC's website [3]. Group 4: Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to engage and modulate disease-specific T cells for autoimmune disease treatment [5]. - The company's proprietary platform, Immuno-STAT®, aims to harness the immune system's potential without broad systemic immune modulation [5]. - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology and protein engineering [6].